Patents by Inventor Roberta Burden

Roberta Burden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapy targeting cathepsin S
    Patent number: 9321838
    Abstract: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumor cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: April 26, 2016
    Assignee: Fusion Antibodies Limited
    Inventors: Shane Olwill, Christopher Scott, Julie Gormley, Jaquin Thomas, Roberta Burden, Darragh McMeel, James Johnston
  • Antibody and uses thereof
    Patent number: 8747849
    Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 10, 2014
    Assignee: Fusion Antibodies Limited
    Inventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
  • ANTIBODY AND USES THEREOF
    Publication number: 20110243955
    Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity.
    Type: Application
    Filed: March 18, 2011
    Publication date: October 6, 2011
    Applicant: Fusion Antibodies Limited
    Inventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
  • Antibody and uses thereof
    Patent number: 7939642
    Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: May 10, 2011
    Assignee: Fusion Antibodies Limited
    Inventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
  • PEPTIDE AND USES THEREOF
    Publication number: 20100104554
    Abstract: A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described.
    Type: Application
    Filed: March 2, 2007
    Publication date: April 29, 2010
    Applicant: Fusion Antibodies Limited, a Corporation of Great Britian
    Inventors: Christopher Scott, Roberta Burden, Jim Johnston, Mark McCurley, Philip Snoddy, Richard Buick
  • ANTIBODY AND USES THEREOF
    Publication number: 20100086551
    Abstract: A method of inhibiting angiogenesis in a group of cells, a tissue or an organ includes administering an antibody molecule or nucleic acid encoding an antibody molecule to the cells, tissue or organ, wherein the antibody molecule specifically binds cathepsin S, but does not inhibit proteolytic activity of cathepsin S.
    Type: Application
    Filed: October 12, 2007
    Publication date: April 8, 2010
    Applicant: Fusion Antibodies Limited
    Inventors: Shane Olwill, Christopher Scott, James Johnston, Roberta Burden
  • ANTIBODY AND USES THEREOF
    Publication number: 20090317405
    Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
    Type: Application
    Filed: April 10, 2006
    Publication date: December 24, 2009
    Applicant: Fusion Antibodies Limited
    Inventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
  • THERAPY
    Publication number: 20090269360
    Abstract: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.
    Type: Application
    Filed: April 10, 2007
    Publication date: October 29, 2009
    Applicant: Fusion Antibodies Limited
    Inventors: Shane Olwill, Christopher Scott, Julie Gormley, Jaquin Thomas, Roberta Burden, Darragh McMeel, James Johnston
  • Antibody and Uses Thereof
    Publication number: 20090068198
    Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
    Type: Application
    Filed: April 10, 2006
    Publication date: March 12, 2009
    Applicant: The Queen's University of Belfast
    Inventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston